---
document_datetime: 2023-09-21 18:42:15
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/filgrastim-ratiopharm-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: filgrastim-ratiopharm-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 0.7561887
conversion_datetime: 2025-12-20 15:30:33.005286
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

| No        | Scope                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Opinion/ Notification   | Commission Decision          | Product Information Summary                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------|------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0001/G | This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data are submitted by the MAH, C.I.3.a - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under A 45/46, or amendments to reflect a Core SPC - Changes with NO new additional data are submitted by the MAH | issued on 21/02/2011    | Issued 2 / amended on n/a no | affected 3 SPC, Labelling, PL To implement changes requested in the PSUR 3 Assessment Report (dated 06 August 2010), as well as to bring the Product Information in line with the SmPC of the reference product (Neupogen). Minor linguistic amendments are introduced in the Package Leaflet for the following languages: CS, DA, DE, EN, ET, ES, FI, FR, HU, IT, NL, PL . In addition, the MAH amended the European Medicines Agency web address in section 10 of the SmPC. longer |

●

7 Westferry Circus

Canary Wharf

+44 (0)20 7418 8400

●

London E14 4HB

Facsimile

●

United Kingdom

+44 (0) 20 7523 7455

<!-- image -->

<!-- image -->

<!-- image -->

info@ema.europa.eu Website www.ema.europa.eu An agency of the European Union Filgrastim ratiopharm Procedural steps taken and scientific information after the authorisation 1 Notifications are issued for type I variations (unless part of a group or a worksharing application). Opinions are issued for all other procedures. 2 No Commission Decision is issued for type IA and type IB variations or for type II variations and annual re-assessments that do not affect the annexes. 3 SPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). Medicinal product no longer authorised